Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

1062 result(s) found, displaying 301 to 325

  • AusPAR: Isatuximab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Isatuximab

  • AusPAR: Cemiplimab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Cemiplimab

  • AusPAR: Melatonin

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Melatonin

  • AusPAR: Vonicog alfa

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Vonicog alfa

  • AusPAR: Venetoclax

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Venetoclax 

  • AusPAR: Gemtuzumab ozogamicin

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Gemtuzumab ozogamicin

  • AusPAR: Venetoclax

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Venetoclax

  • AusPAR: Adalimumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Gilteritinib (as fumarate)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Xospata (gilteritinib as fumarate) for the treatment of relapsed or refractory acute myeloid leukaemia (AML)

  • AusPAR: Ranibizumab (rbe)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Lucentis (ranibizumab) for the treatment of retinopathy of prematurity (ROP)

  • AusPAR: Tafamidis and Tafamidis meglumine

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine) for the treatment of transthyretin amyloid cardiomyopathy

  • AusPAR: Alpelisib

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Piqray (alpelisib), in combination with fulvestrant, for the treatment of advanced or metastatic breast cancer

  • AusPAR: Tocilizumab (rch)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Actemra (tocilizumab) for the treatment of systemic juvenile idiopathic arthritis

  • AusPAR: Insulin aspart (rys)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Fiasp, Fiasp Penfill, Fiasp FlexTouch (insulin aspart rys) for the treatment of diabetes mellitus

  • AusPAR: Enoxaparin sodium

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Enoxaparin sodium

  • AusPAR: Darolutamide

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Darolutamide

  • AusPAR: Remdesivir

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Remdesivir

  • AusPAR: Ribociclib succinate

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ribociclib succinate

  • AusPAR: Ixekizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ixekizumab

  • AusPAR: Infliximab (rmc)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Infliximab (rmc)

  • AusPAR: Dinutuximab beta

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Dinutuximab beta

  • AusPAR: Atezolizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Atezolizumab

Help us improve the Therapeutic Goods Administration site